This is the ValueSet that contains all the codes in Vaccines - IPS (http://hl7.org/fhir/uv/ips/ValueSet/vaccines-uv-ips) and CVX Vaccines Administered Vaccine Set (http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1010.6). E.g. what you have to deal with if you get resources containing codes in either of them
Generated Narrative: ValueSet 87c237b3-3779-4a46-aa9d-2fef1630e941-107
This value set includes codes based on the following rules:
http://snomed.info/sct version Not Stated (use latest from terminology server) where concept descends from 787859002 (Vaccine product)http://snomed.info/sct version Not Stated (use latest from terminology server) where concept is-a 787482006 (No known immunizations)http://hl7.org/fhir/sid/cvx version Not Stated (use latest from terminology server)| Code | Display |
| 01 | diphtheria, tetanus toxoids and pertussis vaccine |
| 02 | trivalent poliovirus vaccine, live, oral |
| 03 | measles, mumps and rubella virus vaccine |
| 04 | measles and rubella virus vaccine |
| 05 | measles virus vaccine |
| 06 | rubella virus vaccine |
| 07 | mumps virus vaccine |
| 08 | hepatitis B vaccine, pediatric or pediatric/adolescent dosage |
| 09 | tetanus and diphtheria toxoids, adsorbed, preservative free, for adult use (2 Lf of tetanus toxoid and 2 Lf of diphtheria toxoid) |
| 10 | poliovirus vaccine, inactivated |
| 100 | pneumococcal conjugate vaccine, 7 valent |
| 101 | typhoid Vi capsular polysaccharide vaccine |
| 102 | DTP- Haemophilus influenzae type b conjugate and hepatitis b vaccine |
| 103 | meningococcal C conjugate vaccine |
| 104 | hepatitis A and hepatitis B vaccine |
| 105 | vaccinia (smallpox) vaccine, diluted |
| 106 | diphtheria, tetanus toxoids and acellular pertussis vaccine, 5 pertussis antigens |
| 107 | diphtheria, tetanus toxoids and acellular pertussis vaccine, unspecified formulation |
| 108 | meningococcal ACWY vaccine, unspecified formulation |
| 109 | pneumococcal vaccine, unspecified formulation |
| 11 | pertussis vaccine |
| 110 | DTaP-hepatitis B and poliovirus vaccine |
| 111 | Influenza, live, trivalent, intranasal |
| 112 | tetanus toxoid, unspecified formulation |
| 113 | tetanus and diphtheria toxoids, adsorbed, preservative free, for adult use (5 Lf of tetanus toxoid and 2 Lf of diphtheria toxoid) |
| 114 | meningococcal polysaccharide (groups A, C, Y and W-135) diphtheria toxoid conjugate vaccine (MCV4P) |
| 115 | tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine, adsorbed |
| 116 | rotavirus, live, pentavalent vaccine |
| 118 | human papilloma virus vaccine, bivalent |
| 119 | rotavirus, live, monovalent vaccine |
| 120 | diphtheria, tetanus toxoids and acellular pertussis vaccine, Haemophilus influenzae type b conjugate, and poliovirus vaccine, inactivated (DTaP-Hib-IPV) |
| 121 | zoster vaccine, live |
| 122 | rotavirus vaccine, unspecified formulation |
| 123 | influenza virus vaccine, H5N1, A/Vietnam/1203/2004 (national stockpile) |
| 125 | Novel Influenza-H1N1-09, live virus for nasal administration |
| 126 | Novel influenza-H1N1-09, preservative-free, injectable |
| 127 | Novel influenza-H1N1-09, injectable |
| 128 | Novel influenza-H1N1-09, all formulations |
| 129 | Japanese Encephalitis vaccine, unspecified formulation |
| 130 | Diphtheria, tetanus toxoids and acellular pertussis vaccine, and poliovirus vaccine, inactivated |
| 131 | Historical record of a typhus vaccination |
| 132 | Historical diphtheria and tetanus toxoids and acellular pertussis, poliovirus, Haemophilus b conjugate and hepatitis B (recombinant) vaccine. |
| 133 | pneumococcal conjugate vaccine, 13 valent |
| 134 | Japanese Encephalitis vaccine for intramuscular administration |
| 135 | Influenza, high-dose, split virus, trivalent, injectable, preservative free |
| 136 | meningococcal oligosaccharide (groups A, C, Y and W-135) diphtheria toxoid conjugate vaccine (MCV4O) |
| 137 | HPV, unspecified formulation |
| 138 | tetanus and diphtheria toxoids, not adsorbed, for adult use |
| 139 | Td(adult) unspecified formulation |
| 140 | Influenza, split virus, trivalent, injectable, preservative free |
| 141 | Influenza, split virus, trivalent, injectable, contains preservative |
| 142 | tetanus toxoid, not adsorbed |
| 143 | Adenovirus, type 4 and type 7, live, oral |
| 144 | seasonal influenza, intradermal, preservative free |
| 146 | Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate (Meningococcal Protein Conjugate), and Hepatitis B (Recombinant) Vaccine. |
| 147 | Meningococcal, MCV4, unspecified conjugate formulation(groups A, C, Y and W-135) |
| 148 | Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine |
| 149 | Influenza, live, quadrivalent, intranasal |
| 15 | influenza virus vaccine, split virus (incl. purified surface antigen)-retired CODE |
| 150 | Influenza, split virus, quadrivalent, injectable, preservative free |
| 151 | influenza nasal, unspecified formulation |
| 152 | Pneumococcal Conjugate, unspecified formulation |
| 153 | Influenza, Madin Darby Canine Kidney, subunit, trivalent, injectable, preservative free |
| 155 | Influenza, recombinant, trivalent, injectable, preservative free |
| 158 | Influenza, split virus, quadrivalent, injectable, contains preservative |
| 16 | influenza virus vaccine, whole virus |
| 160 | Influenza A monovalent (H5N1), adjuvanted, National stockpile 2013 |
| 161 | Influenza, injectable,quadrivalent, preservative free, pediatric |
| 162 | meningococcal B vaccine, fully recombinant |
| 163 | meningococcal B vaccine, recombinant, OMV, adjuvanted |
| 164 | meningococcal B, unspecified formulation |
| 165 | Human Papillomavirus 9-valent vaccine |
| 166 | influenza, intradermal, quadrivalent, preservative free, injectable |
| 167 | meningococcal vaccine of unknown formulation and unknown serogroups |
| 168 | Influenza, adjuvanted, inactivated, trivalent, injectable, preservative free |
| 169 | Hep A, live attenuated-IM |
| 17 | Haemophilus influenzae type b vaccine, conjugate unspecified formulation |
| 170 | non-US diphtheria, tetanus toxoids and acellular pertussis vaccine, Haemophilus influenzae type b conjugate, and poliovirus vaccine, inactivated (DTaP-Hib-IPV) |
| 171 | Influenza, Madin Darby Canine Kidney, subunit, quadrivalent, injectable, preservative free |
| 172 | cholera, WC-rBS |
| 173 | cholera, BivWC |
| 174 | cholera, live attenuated |
| 175 | Human Rabies vaccine from human diploid cell culture |
| 176 | Human rabies vaccine from Chicken fibroblast culture |
| 177 | pneumococcal conjugate vaccine, 10 valent |
| 178 | Non-US bivalent oral polio vaccine (types 1 and 3) |
| 179 | Non-US monovalent oral polio vaccine, unspecified formulation |
| 18 | rabies vaccine, for intramuscular injection RETIRED CODE |
| 182 | Oral Polio Vaccine, Unspecified formulation |
| 183 | Yellow fever vaccine live - alternative formulation for vaccine shortage |
| 184 | Yellow fever vaccine, unspecified formulation |
| 185 | Influenza, recombinant, quadrivalent, injectable, preservative free |
| 186 | Influenza, Madin Darby Canine Kidney, subunit, quadrivalent, injectable, contains preservative |
| 187 | zoster vaccine recombinant |
| 188 | zoster vaccine, unspecified formulation |
| 189 | Hepatitis B vaccine (recombinant), CpG adjuvanted |
| 19 | Bacillus Calmette-Guerin vaccine |
| 190 | Typhoid conjugate vaccine (non-US) |
| 191 | meningococcal A polysaccharide vaccine (non-US) |
| 192 | meningococcal AC polysaccharide vaccine (non-US) |
| 193 | hepatitis A and hepatitis B vaccine, pediatric/adolescent (non-US) |
| 194 | influenza, Southern Hemisphere, unspecified formulation |
| 195 | Diphtheria, Tetanus, Poliomyelitis adsorbed |
| 196 | tetanus and diphtheria toxoids, adsorbed, preservative free, for adult use, Lf unspecified |
| 197 | Influenza, high-dose, split virus, quadrivalent, injectable, preservative free |
| 198 | Diphtheria, pertussis, tetanus, hepatitis B, Haemophilus Influenza Type b, (Pentavalent) |
| 20 | diphtheria, tetanus toxoids and acellular pertussis vaccine |
| 200 | influenza, seasonal, Southern Hemisphere, quadrivalent, pediatric 0.25mL dose, preservative free |
| 201 | influenza, seasonal, Southern Hemisphere, quadrivalent, 0.5mL dose, no preservative |
| 202 | influenza, seasonal, Southern Hemisphere, quadrivalent, 0.5mL dose, with preservative |
| 203 | meningococcal polysaccharide (groups A, C, Y, W-135) tetanus toxoid conjugate vaccine 0.5mL dose, preservative free |
| 204 | Ebola Zaire vaccine, live, recombinant, 1mL dose |
| 205 | Influenza, adjuvanted, inactivated, quadrivalent, injectable, preservative free |
| 206 | Vaccinia, smallpox monkeypox vaccine, live attenuated, preservative free, subcutaneous or intradermal injection |
| 207 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose |
| 208 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose |
| 21 | varicella virus vaccine |
| 210 | SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-ChAdOx1, preservative free, 0.5 mL |
| 211 | SARS-COV-2 (COVID-19) vaccine, subunit, recombinant spike protein-nanoparticle+Matrix-M1 Adjuvant, preservative free, 0.5mL dose |
| 212 | SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL |
| 213 | SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED |
| 214 | Ebola, unspecified |
| 215 | Pneumococcal conjugate vaccine 15-valent (PCV15), polysaccharide CRM197 conjugate, adjuvant, preservative free |
| 216 | Pneumococcal conjugate vaccine 20-valent (PCV20), polysaccharide CRM197 conjugate, adjuvant, preservative free |
| 217 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose, tris-sucrose formulation |
| 218 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 10 mcg/0.2mL dose, tris-sucrose formulation |
| 219 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 3 mcg/0.2mL dose, tris-sucrose formulation |
| 22 | DTP-Haemophilus influenzae type b conjugate vaccine |
| 220 | Hepatitis B vaccine (recombinant), 3-antigen, Al(OH)3 adjuvanted |
| 221 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 50 mcg/0.5 mL dose |
| 222 | Tick-borne encephalitis vaccine, unspecified |
| 223 | Tick-borne encephalitis vaccine, inactivated, preservative free, 0.25mL dose |
| 224 | Tick-borne encephalitis vaccine, inactivated, preservative free, 0.5mL dose |
| 227 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, pediatric 50 mcg/0.5 mL dose |
| 228 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, pediatric 25 mcg/0.25 mL dose |
| 229 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 50 mcg/0.5 mL or 25 mcg/0.25 mL dose |
| 23 | plague vaccine |
| 230 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 10 mcg/0.2 mL dose |
| 231 | influenza, seasonal, Southern Hemisphere, high-dose, quadrivalent, 0.7mL dose, preservative free |
| 24 | Anthrax vaccine, adsorbed, pre-exposure and post-exposure prophylaxis |
| 25 | typhoid vaccine, live, oral |
| 26 | cholera vaccine, unspecified formulation |
| 28 | diphtheria and tetanus toxoids, adsorbed for pediatric use |
| 300 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 30 mcg/0.3 mL dose, tris-sucrose formulation |
| 301 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 10 mcg/0.2 mL dose, tris-sucrose formulation |
| 302 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 3 mcg/0.2 mL dose, tris-sucrose formulation |
| 303 | Respiratory syncytial virus (RSV), vaccine, recombinant, protein subunit RSV prefusion F, adjuvant reconstituted, 0.5 mL, preservative free |
| 304 | Respiratory syncytial virus (RSV), unspecified |
| 305 | Respiratory syncytial virus (RSV), vaccine, bivalent, protein subunit RSV prefusion F, diluent reconstituted, 0.5 mL, preservative free |
| 306 | Respiratory syncytial virus (RSV) monoclonal antibody, IgG1κ, (nirsevimab-alip), 0.5 mL, neonates and children to 24 months |
| 307 | Respiratory syncytial virus (RSV) monoclonal antibody, IgG1κ, (nirsevimab-alip), 1 mL, neonates and children to 24 months |
| 308 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 3 mcg/0.3 mL dose |
| 309 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 30 mcg/0.3 mL dose |
| 31 | hepatitis A vaccine, pediatric dosage, unspecified formulation |
| 310 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 10 mcg/0.3 mL dose |
| 311 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 25 mcg/0.25 mL dose |
| 312 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 50 mcg/0.5 mL dose |
| 313 | SARS-COV-2 (COVID-19) vaccine, subunit, recombinant spike protein-nanoparticle+Matrix-M1 Adjuvant, preservative free, 5 mcg/0.5 mL dose |
| 314 | Respiratory syncytial virus (RSV) vaccine, unspecified |
| 315 | Respiratory syncytial virus (RSV) monoclonal antibody (MAB), unspecified |
| 316 | Meningococcal polysaccharide (groups A, C, Y, W) tetanus toxoid conjugate, meningococcal B recombinant vaccine, 0.5mL, preservative free |
| 317 | Chikungunya, live attenuated vaccine, 0.5 mL, preservative free |
| 318 | Anthrax vaccine, adsorbed, adjuvanted, post-exposure prophylaxis |
| 319 | Anthrax vaccine, unspecified |
| 32 | meningococcal polysaccharide vaccine (MPSV4) |
| 320 | Influenza, Madin Darby Canine Kidney, subunit, trivalent, injectable, contains preservative |
| 321 | Influenza-avian, H5N8, viral-vector, monovalent, injectable, preservative free |
| 322 | Influenza-avian, H5N8, viral-vector, monovalent, injectable, contains preservative |
| 323 | Influenza-avian, H5, unspecified formulation |
| 324 | Poliovirus, inactivated, fractional-dose (fIPV) |
| 326 | Respiratory syncytial virus (RSV), mRNA, injectable, preservative free |
| 327 | Pneumococcal conjugate vaccine, 21 valent (PCV21), polysaccharide CRM197 conjugate, preservative free |
| 33 | pneumococcal polysaccharide vaccine, 23 valent |
| 35 | tetanus toxoid, adsorbed |
| 37 | yellow fever vaccine live |
| 38 | rubella and mumps virus vaccine |
| 39 | Japanese Encephalitis Vaccine SC |
| 40 | rabies vaccine, for intradermal injection |
| 41 | typhoid vaccine, parenteral, other than acetone-killed, dried |
| 42 | hepatitis B vaccine, adolescent/high risk infant dosage |
| 43 | hepatitis B vaccine, adult dosage |
| 44 | Hepatitis B vaccine (Hep B), high-dosage, dialysis or immunocompromised patient |
| 45 | hepatitis B vaccine, unspecified formulation |
| 46 | Haemophilus influenzae type b vaccine, PRP-D conjugate |
| 47 | Haemophilus influenzae type b vaccine, HbOC conjugate |
| 48 | Haemophilus influenzae type b vaccine, PRP-T conjugate |
| 49 | Haemophilus influenzae type b vaccine, PRP-OMP conjugate |
| 50 | DTaP-Haemophilus influenzae type b conjugate vaccine |
| 500 | SARS-COV-2 COVID-19 Non-US Vaccine, Specific Product Unknown |
| 501 | SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (QAZCOVID-IN) |
| 502 | SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (COVAXIN) |
| 503 | SARS-COV-2 COVID-19 Live Attenuated Virus Non-US Vaccine Product (COVIVAC) |
| 504 | SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (Sputnik Light) |
| 505 | SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (Sputnik V) |
| 506 | SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (CONVIDECIA), CanSino Biological Inc./Beijing Institute of Biotechnology |
| 507 | SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbiology, Chinese Academy of Sciences) |
| 508 | SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Jiangsu Province Centers for Disease Control and Prevention) |
| 509 | SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (EpiVacCorona) |
| 51 | Haemophilus influenzae type b conjugate and Hepatitis B vaccine |
| 510 | SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (BIBP, Sinopharm) |
| 511 | SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (CoronaVac, Sinovac) |
| 512 | SARS-COV-2 COVID-19 Virus Like Particle (VLP) Non-US Vaccine Product (Medicago, Covifenz) |
| 513 | SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Anhui Zhifei Longcom, Zifivax) |
| 514 | SARS-COV-2 COVID-19 DNA Non-US Vaccine Product (Zydus Cadila, ZyCoV-D) |
| 515 | SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Medigen, MVC-COV1901) |
| 516 | SARS-COV-2 COVID-19 Inactivated Non-US Vaccine Product (Minhai Biotechnology Co, KCONVAC) |
| 517 | SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Biological E Limited, Corbevax) |
| 518 | SARS-COV-2 COVID-19 Inactivated, Non-US Vaccine (VLA2001, Valneva) |
| 519 | SARS-COV-2 COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine (Spikevax Bivalent), Moderna |
| 52 | hepatitis A vaccine, adult dosage |
| 520 | SARS-COV-2 COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine Product (Comirnaty Bivalent), Pfizer-BioNTech |
| 521 | SARS-COV-2 (COVID-19) vaccine SP, protein-based, adjuvanted, B.1.351 strain (VidPrevtyn Beta), Sanofi-GSK |
| 53 | typhoid vaccine, parenteral, acetone-killed, dried (U.S. military) |
| 54 | adenovirus vaccine, type 4, live, oral |
| 55 | adenovirus vaccine, type 7, live, oral |
| 56 | dengue fever vaccine, tetravalent |
| 62 | human papilloma virus vaccine, quadrivalent |
| 66 | Lyme disease vaccine |
| 69 | parainfluenza-3 virus vaccine |
| 74 | rotavirus, live, tetravalent vaccine |
| 75 | vaccinia (smallpox) vaccine |
| 77 | Tick-borne encephalitis vaccine (non-US) |
| 78 | tularemia vaccine |
| 80 | Venezuelan equine encephalitis, live, attenuated |
| 81 | Venezuelan equine encephalitis, inactivated |
| 82 | adenovirus vaccine, unspecified formulation |
| 83 | hepatitis A vaccine, pediatric/adolescent dosage, 2 dose schedule |
| 84 | hepatitis A vaccine, pediatric/adolescent dosage, 3 dose schedule |
| 85 | hepatitis A vaccine, unspecified formulation |
| 88 | influenza virus vaccine, unspecified formulation |
| 89 | poliovirus vaccine, unspecified formulation |
| 90 | rabies vaccine, unspecified formulation |
| 91 | typhoid vaccine, unspecified formulation |
| 92 | Venezuelan equine encephalitis vaccine, unspecified formulation |
| 94 | measles, mumps, rubella, and varicella virus vaccine |